

Content available at: <https://www.ipinnovative.com/open-access-journals>

IP International Journal of Ocular Oncology and Oculoplasty

Journal homepage: <https://ijooo.org/>

Original Research Article

Ocular morbidity in patients on long-term selective serotonin reuptake inhibitors (SSRIs)

Pooja H V¹, H T Venkate Gowda¹, Rao Vaishnavi Prasad^{1,*}¹Dept. of Ophthalmology, Adichunchanagiri Institute of Medical Sciences College, Adichunchanagiri University, B G Nagar, Mandya, Karnataka, India

ARTICLE INFO

Article history:

Received 09-09-2021

Accepted 22-10-2021

Available online 07-02-2022

Keywords:

SSRI

Dry eye

Cataract

Glaucoma

ABSTRACT

Purpose: To assess ocular morbidity in patients on long time anti-psychotic medication- SSRI.**Materials and Methods:** Cross-sectional observational study was conducted on 96 patients on anti-psychotic medication (SSRI) who attended the OPD in Department of Ophthalmology and Psychiatry, from July 2019 to July 2021.**Results:** Of 96 patients, 71(73.9%) patients had ocular morbidity. Most common ocular morbidities were dry eye 62 (87.3%) followed by, reduced corneal sensitivity 3(4.2%), cataract 3 (4.2%), glaucoma 2(2.8%), ischemic optic neuropathy 1 (1.4%).**Conclusion:** Dry eye was the most common ocular morbidity seen. SSRIs on long term usage have significant ocular side effects, which should be kept in mind by both Ophthalmologists and Psychiatrics in their clinical practise.This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.For reprints contact: reprint@ipinnovative.com

1. Introduction

Major depressive disorder (MDD), among the psychiatric conditions, is one of the leading causes of global disability-adjusted life years (DALYs).¹ In the recent statistics of 2019, its been ranked 11th globally as leading cause of DALYs which had significantly increased from the 15th rank in 1990.² Anti-depressant medications include Selective serotonin reuptake inhibitors (SSRIs), selective Norepinephrine Reuptake Inhibitors (SNRIs) and Tri Cyclic Antidepressants (TCA). Among them, SSRIs are the most commonly prescribed drugs for MDD.³

Serotonin (5-hydroxytryptamine, 5-HT), a biogenic monoamine, has various actions on the both central and the peripheral nervous systems.⁴ Serotonin and its receptors are found in different ocular structures such as cornea, iris, ciliary muscle, iris sphincter muscle, lens and retina.

Serotonin has varied actions in numerous ocular tissues like- 5-HT_{1A} receptors found in the iris and ciliary body reduce the production of aqueous humour, thus decreasing the intraocular pressure; In contrast, aqueous humour synthesis is increased via 5-HT₇ receptors and they also induce mydriasis by relaxing the pupillary sphincter. The 5-HT_{2A/2C} receptor play a significant role in the corneal homeostasis.⁴

Selective serotonin reuptake inhibitors (SSRIs) increase availability of serotonin by inhibiting pre-synaptic serotonin transport. This effect has been used in the treatment of depression, anxiety and other mood disorders such as eating disorders.⁵ SSRIs group consists of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline. Along with these advantages, this group has disabling systemic side effects such as weight gain, insomnia, increased appetite, vertigo, nausea, sexual problems, itching. Various previous studies have

* Corresponding author.

E-mail address: raovaishnavi24@gmail.com (R. V. Prasad).

documented SSRIs ocular side effects such as cataracts,^{6,7} central retinal vein occlusion⁸, acute angle-closure glaucoma,⁹ optic neuropathy¹⁰ and diplopia.¹¹ However, these studies are not well researched in humans.^{12,13}

SSRIs are among the first-line medication for MDD and since cataracts, glaucoma are the leading cause of blindness, it has become more pertinent to assess the ocular side effects of SSRIs for follow up monitoring and providing advice to patients.

2. Materials and Methods

A Cross sectional observational study of 96 patients diagnosed with depression based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, and a history of SSRIs usage at least for 6 weeks in psychiatry and ophthalmology outpatient clinics between the time period of July 2019 to July 2021, were included.

The study was conducted after approval from the ethics committee. Patients were explained about the study in their own understandable language and individual written informed consent was taken. All subjects were questioned about age, sex, gender, demographic details, history of any other systemic diseases, medications. Patients taking SSRI for more than 6 months were included in the study. Patient underwent routine ophthalmic examination which included best corrected visual acuity, retinoscopy, corneal sensation, Schirmer's test, slit lamp examination for thorough anterior segment evaluation TBUT, cataract if present was graded using LOCS III classification. Intraocular pressure examination by rebound tonometer, gonioscopy using Zeiss four mirror gonioscope and fundus examination using both direct and indirect ophthalmoscope using 20D lenses, 90D lens.

We adjusted for potential confounding variables, including age, gender, income, urbanization, hypertension, diabetes and hypercholesterolemia, prescriptions with antipsychotics, anticholinergics, topiramate, steroids, hormone replacement treatment, and other antidepressants: tricyclic antidepressants, as possible confounding factors.

3. Results

Out of 96 patients, 32 were men and 64 were women. Age of patients in our study was on an average 46.64 years. The mean duration of SSRI usage was 24±3 months. In our study, 81 (81.4%) patients were diagnosed with depression, 5 (5.2%) patients diagnosed with depression with anxiety disorder and 10 (10.4%) patients were diagnosed with generalised anxiety disorder. Fluoxetine was the most commonly prescribed SSRI (37.5%) and out of 96 patients, 71 (73.9%) patients had ocular morbidity. Dry eye was most commonly seen comprising of 62 (87.3%) of cases. Reduced corneal sensitivity 3 (4.2%) patients, cataract 3

(4.2%) patients, glaucoma in 2(2.8%) patients and ischemic optic neuropathy in 1 (1.4%) patient.

Table 1: Sociodemographic variables of patient on SSRI.

Variables	Numbers
Age (years)	46.64 ± 12 years
Gender (M: F)	1:2 (M - 32, F – 64)
Duration of SSRI usage, months	24± 3 months

Table 2: Diagnosis of psychiatric condition.

Type of psychiatric disease	Number (%)
Depression	81 (81.4%)
Depression with anxiety disorder	5 (5.2%)
Generalized anxiety disorder	10 (10.4%)

Table 3: SSRI used in the study.

SSRI	Number (%)
Sertraline	28 (29.1%)
Fluoxetine	46 (37.5%)
Paroxetine	10 (10.4%)
Escitalopram	5 (5.2%)

Table 4: Associated ocular morbidity.

Ocular morbidity	Number (%)
Dry eye	62 (87.3%)
Reduced corneal sensitivity	3 (4.2%)
Glaucoma	2 (2.8%)
Cataract	3 (4.2%)
Ischemic optic neuropathy	1 (1.4%)

4. Discussion

Dry eye (DE) is a frequently under-recognized clinical condition characterised by ocular discomfort due to tear deficiency or excessive evaporation.^{14–17} Previously numerous studies, including population based epidemiological studies, have shown a strong link between the use of antidepressant medications and increased risk of dry eye,^{18,19} The proposed mechanism for altered tear film production is its inhibition of muscarinic receptors.²⁰ Various types of serotonin receptors have been identified in the conjunctival and corneal epithelium. SSRIs by altering the level of serotonin can affect the sensitivity thresholds of corneal nerves.²¹ Escitalopram, among the SSRI, seems to cause this side effect significantly.²² In our study we found that 87.3 % patients suffered from dry eye and 4.2% patients had reduced corneal sensitivity. This in concordance with other studies like Kocer E et al, in which dry eye was seen in 35% of patients.²² Wen W et al study which included 472 patients, concluded that long term SSRIs usage had an increased risk of dry eye.

Even though the role of serotonin in lens metabolism remains unidentified, in the animal models- large number of serotonin receptors have been found in the crystalline lens²³ and also altered serotonin levels cause lens opacities in rats.²⁴ In our study 4.2% patients had developed cataract. This is in-line with other population-based study like the study of Erie et al,²⁵ which showed that in patients over 50 years using SSRI for 1 year or more, had significantly increased risk of cataract surgery. Among the SSRIs, citalopram had the highest association.²⁶ The association of SSRI usage and increased incidence of cataract has been proven by various meta-analysis- like the 2018 Fu Y et al study from China, where they found this significant with fluoxetine and fluvoxamine administration. Other SSRIs were not associated with the risk of cataract development.²⁷

SSRIs alter the intraocular pressure via serotonergic effects on ciliary body and pupil dilation. 5-HT_{1A} receptors of iris and ciliary body reduce the intra-ocular pressure by decreasing aqueous humour production. Long term use of SSRIs may lead to altered sensitivity of these receptors resulting in increased intra ocular pressure. 5-HT₇ receptors present in the pupil sphincter, causes mydriasis by relaxation of the sphincter muscle. In patients with narrow iridocorneal angle, this effect can precipitate a glaucomatous attack. In our study, we found 2.8 % patients to have angle closure glaucoma. In a recent study Chen et al, there was a 5.8-fold elevated risk for acute angle closure glaucoma within 7 days initiation of SSRIs usage.¹³ But this association was not significant on a longer usage, like Chen et al study, where they reported that long-term use (>1 year) of SSRIs was not associated with increased risk of both primary open-angle or angle-closure glaucoma (POAG/PACG) in patients with depression. However, this study included only population of Major Depressive Disorder (MDD).²⁸ Several animal and human studies have reported that fluoxetine is associated with significant elevation in intraocular pressure (IOP).²⁹

In our study, we had 1 case of ischemic optic neuropathy. Costagliola postulated that increased plasma serotonin level may be responsible for vasospasm leading to decreased optic nerve perfusion. Patients with atherosclerosis have higher risk of serotonin enhanced platelet aggregation in atheroma of ocular arteries. Thus, both multiple transient vasospasm and increased platelet aggregation cause optic neuropathy.^{30,31} Rarely this non-vasculitis ischaemic optic neuropathy has vision recovery. These patients are on long term SSRIs, mean of 7 years (range 1–14 years) and thus this side effects may be cumulative result of prolonged treatment.³²

This vision threatening vascular side effects should be kept in mind. Precaution must be taken while prescribing SSRIs in conjunction with known systemic vascular risk factors or pre-existing vascular eye disease until the origin of this neuropathy becomes clearer.

5. Conclusion

In our study, dry eye was most common ocular morbidity among the patients on SSRI. The vast majority of drug-induced ocular disorders could easily be prevented and monitored, provided that clinicians and patients become aware of and watchful for ocular signs and symptoms.

6. Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

7. Source of Funding

None.

References

- Murray CJ, Lopez AD. Measuring the Global Burden of Disease. *The N Engl J Med*. 2013;369(5):448–57. doi:10.1056/NEJMra1201534.
- Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2010;380(9859):2197–23. doi:10.1016/S0140-6736(12)61689-4.
- Costagliola C, Parmeggiani F, Semeraro F, Sebastiani A. Selective Serotonin Reuptake Inhibitors: A Review of its Effects on Intraocular Pressure. *Curr Neuropharmacol*. 2008;6(4):293–10. doi:10.2174/157015908787386104.
- Osborne NN. Assay distribution and function of serotonin in nervous tissue Biology of serotonergic transmission. In: Osborne NN, editor. Biology of serotonergic transmission. Chichester: J Wiley & Sons Inc; 1982. p. 7–27.
- NICE Clinical Guidelines. CG90. Depression in adults: the treatment and management of depression in adults. Appendix 19: clinical evidence forest plots. National Collaborating Centre for Mental Health (UK). Leicester (UK): British Psychological Society; 2010.
- Kisilevsky E, Margolin EA. Case of rapid bilateral cataract development in teenager using selective serotonin reuptake inhibitors. *Can J Ophthalmol*. 2014;49(5):e114–5. doi:10.1016/j.jcjo.2014.06.005.
- Becker C, Jick SS, Meier CR. Selective serotonin reuptake inhibitors and cataract risk. *Ophthalmology*. 2017;124(11):1635–9. doi:10.1016/j.ophtha.2017.05.002.
- Hardisty ADR, Hemmerdinger CM, and SAQ. Citalopram-associated central retinal vein occlusion. *Int Ophthalmol*. 2009;29(4):303–4. doi:10.1007/s10792-008-9231-5.
- Chen HY, Lin CL, Lai SW. Association of selective serotonin reuptake inhibitor use and acute angle-closure glaucoma. *J Clin Psychiatry*. 2016;77(6):e692–6. doi:10.4088/JCP.15m10038.
- Lochhead J. SSRI-associated optic neuropathy. *Eye*. 2015;29(9):1233–5. doi:10.1038/eye.2015.119.
- Eray S, Ucar HN, Vural AP. Sertraline-induced diplopia. *Bul Clin Psychopharmacol*. 2016;26(2):213–4. doi:10.5455/bcp.20160109124021.
- Balikci A, Uzun O, Erdem M. Side effects that cause noncompliance to antidepressant medications in the course of outpatient treatment. *Bul Clin Psychopharmacol*. 2014;24(1):69–75.
- Fu Y, Dai Q, Zhu L. Antidepressants use and risk of cataract development: a systematic review and metaanalysis. *BMC Ophthalmol*. 2018;18(1):31. doi:10.1186/s12886-018-0699-0.
- Perry HD. Dry eye disease: pathophysiology, classification, and diagnosis. *Am J Manag Care*. 2008;14(3):79–87.
- Kim KW, Han SB, Han ER, Woo SJ, Lee JJ, Yoon JC, et al. Association between depression and dry eye disease in an

- elderly population. *Invest Ophthalmol Vis Sci.* 2011;52:7954–8. doi:10.1167/iovs.11-8050.
16. Dorennavar L, Maurya RP, Singh VP, Singh MK, Sharma K, Sharma R, et al. The role of Rebampipde ophthalmic suspension in management of dry eye disease. *Indian J Clin Exp Ophthalmol.* 2015;1(4):191–6.
 17. Maurya RP, Singh VP, Chaudhary S, Roy M, Srivastava T, Rajan M, et al. Prevalence of severe dry eye disease in postmenopausal women in North India A teaching hospital study. *Indian J Obstet Gynecol Res.* 2019;6(1):94–100.
 18. Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. *CNS Drugs.* 2010;24(6):501–26. doi:10.2165/11533180-000000000-00000.
 19. Lee AJ, Lee J, Saw SM. Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia. *Br J Ophthalmol.* 2002;86(12):1347–51. doi:10.1136/bjo.86.12.1347.
 20. Jaanus SD. Ocular side effects of selected systemic drugs. *Optom Clin.* 1992;2(4):73–96.
 21. Martin XD, Brennanmc. Serotonin in human tears. *Eur J Ophthalmol.* 1994;4(3):159–65. doi:10.1177/112067219400400305.
 22. Crider JY, Williams GW, Drace CD. Pharmacological characterization of a serotonin receptor (5-HT7) stimulating cAMP production in human corneal epithelial cells. *Invest Ophthalmol Vis Sci.* 2003;44(11):4837–44. doi:10.1167/iovs.02-1292.
 23. Koçer E, Koçer A, Özsütçü M. Dry Eye Related to Commonly Used New Antidepressants. *J Clin Psychopharmacol.* 2015;35(4):411–3. doi:10.1097/JCP.0000000000000356.
 24. Costagliola C, Parmeggiani, Sebastiani A. SSRIs and intraocular pressure modifications: evidence, therapeutic implications and possible mechanisms. *CNS Drugs.* 2004;18(8):475–84. doi:10.2165/00023210-200418080-00001.
 25. Erie JC, Brue SM, Chamberlain AM. Selective serotonin reuptake inhibitor use and increased risk of cataract surgery: a population-based, case-control study. *Am J Ophthalmol.* 2014;158(1):192–7.
 26. Boerriqter RM, Siertsema JV, Kema IP. Serotonin (5-HT) and the rat's eye: some pilot studies. *Doc Ophthalmol.* 1992;82(1-2):141–50.
 27. Becker C, Jick SS, Meier CR. Selective serotonin reuptake inhibitors and cataract risk. *Ophthalmology.* 2017;124(11):1635–9. doi:10.1016/j.ophtha.2017.05.002.
 28. Chen HY, Lin CL, Lai SW, Kao CH. Association of Selective Serotonin Reuptake Inhibitor Use and Acute Angle-Closure Glaucoma. *J Clin Psychiatry.* 2016;77(6):e692–6. doi:10.4088/JCP.15m10038.
 29. Chen HY, Lin CL, Kao CH. Long-Term Use of Selective Serotonin Reuptake Inhibitors and Risk of Glaucoma in Depression Patients. *Medicine.* 2015;94(45):e2041. doi:10.1097/MD.0000000000002041.
 30. Costagliola C, Mastropasqua L, Capone D, Verolino M, Ciancaglini M, Pisanti N, et al. Effect of fluoxetine on intraocular pressure in the rabbit. *Exp Eye Res.* 2000;70:551–5. doi:10.1006/exer.1999.0773.
 31. Hayreh SS. Retinal and optic nerve head ischemic disorders and atherosclerosis: role of serotonin. *Prog Retin Eye Res.* 1999;18:191–221.
 32. Hayreh SS. Posterior ischaemic optic neuropathy: clinical features, pathogenesis, and management. *Eye.* 2004;18(2):1188–221. doi:10.1016/s1350-9462(98)00016-0.

Author biography

Pooja H V, Assistant Professor

H T Venkate Gowda, Professor and Head

Rao Vaishnavi Prasad, Junior Resident

Cite this article: Pooja H V, Gowda HTV, Prasad RV. Ocular morbidity in patients on long-term selective serotonin reuptake inhibitors (SSRIs). *IP Int J Ocul Oncol Oculoplasty* 2021;7(4):364-367.